{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(27)"],"submitter":["You B"],"pubmed_abstract":["Purpose
Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative chemotherapy regimens, which, although effective, cause considerable toxicity. All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells are involved in trophoblast immunosurveillance. Avelumab (anti-PD-L1) induces NK cell-mediated cytotoxicity. The TROPHIMMUN trial assessed avelumab in women with chemotherapy-resistant GTT.Methods
In this phase II multicenter trial (ClinicalTrials.gov identifier: NCT03135769), women with GTT who experienced disease progression after single-agent chemotherapy received avelumab 10 mg/kg intravenously every 2 weeks until human chorionic gonadotropin (hCG) normalization, followed by 3 consolidatio"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["3129-3137"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7499607"],"repository":["biostudies-literature"],"pubmed_title":["Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial."],"pmcid":["PMC7499607"],"pubmed_authors":["Roux A","Lotz JP","Massardier J","Bin S","Mercier C","Maucort-Boulch D","Grazziotin-Soares D","Joly F","Hajri T","Alves-Ferreira M","Langlois-Jacques C","Bolze PA","Devouassoux-Shisheboran M","Golfier F","Gladieff L","You B","Villeneuve L","Freyer G","Rousset P"],"additional_accession":[]},"is_claimable":false,"name":"Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.","description":"Purpose
Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alternative chemotherapy regimens, which, although effective, cause considerable toxicity. All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells are involved in trophoblast immunosurveillance. Avelumab (anti-PD-L1) induces NK cell-mediated cytotoxicity. The TROPHIMMUN trial assessed avelumab in women with chemotherapy-resistant GTT.Methods
In this phase II multicenter trial (ClinicalTrials.gov identifier: NCT03135769), women with GTT who experienced disease progression after single-agent chemotherapy received avelumab 10 mg/kg intravenously every 2 weeks until human chorionic gonadotropin (hCG) normalization, followed by 3 consolidatio","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2025-04-19T09:43:41.975Z","creation":"2022-02-11T11:07:57.049Z"},"accession":"S-EPMC7499607","cross_references":{"pubmed":["32716740"],"doi":["10.1200/JCO.20.00803"]}}